Seminars in Oncology
Volume 30, Issue 2 , Pages 127-131, April 2003

Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia☆☆

University of Texas, M.D. Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; UCLA Medical Center, Los Angeles, CA; Arthur James Comprehensive Cancer Center, Ohio State University, Columbus, OH; Institute of Hematology and Oncology, University of Barcelona, Barcelona, Spain; and the Karolinska Institutet, Department of Hematology, Huddinge University Hospital, Stockholm, Sweden

Abstract 

Waldenstrom's macroglobulinemia (WM) is a malignant disorder of lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM). Since the original description by Jan Waldenström of three patients with symptoms of hyperviscosity due to circulating monoclonal IgM, the definition of WM has been controversial. Standardized criteria for diagnosis have now been proposed, including the presence of any IgM monoclonal protein and marrow and/or nodal lymphoplasmacytic cells. Although previous response criteria have generally incorporated parameters for monoclonal protein reduction and/or improvement of marrow/nodal involvement, specific and uniform response criteria are needed to facilitate comparisons of response, remission duration, progression-free survival, and overall survival in clinical trials similar to those previously established for other diseases such as chronic lymphocytic leukemia, lymphoma, and myeloma. This is of particular importance as new agents are developed and evaluated. This presentation represents consensus recommendations for uniform response criteria for use in assessing responses to treatment for patients with WM, which were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002. Semin Oncol 30:127-131. © 2003 Elsevier Inc. All rights reserved.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Address reprint requests to Waldenstrom's Macroglobulinemia Program, Dana Farber Cancer Institute, Harvard Medical School, LG100, 44 Binney St, Boston, MA 02115. Email: wmp@dfci.harvard.edu.

☆☆ 0093-7754/03/3002-0001$30.00/0

PII: S0093-7754(03)70062-1

doi:10.1053/sonc.2003.50037

Seminars in Oncology
Volume 30, Issue 2 , Pages 127-131, April 2003